Follow us on Twitter
twitter icon@FreshPatents


Allergy patents

      

This page is updated frequently with new Allergy-related patent applications.

Allergy warning and protection system with beacon enhanced wearable for proactive transmission and communication of allergy information
An allergy warning and protection system and method to proactively warn a user and protect a dependent individual, such as a child, suffering from allergies. The system comprises a beacon housed within a wearable, such as a bracelet, that is worn by the dependent.

Sulfinylphenyl or sulfonimidoylphenyl benzazepines
Wherein x and r1 to r6 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are tlr agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases..

Quail egg allergy antigen
The present invention provides novel antigens of an allergy to a quail egg, methods and kits for diagnosing an allergy to a quail egg, pharmaceutical compositions comprising such an antigen, and quail eggs or processed products of quail egg which are devoid of such an antigen.. .
Hoyu Co., Ltd.


Allergy-specific immunotherapy compositions for use in the treatment of house-dust mite allergy
The present invention relates to a composition comprising purified natural der p1 and purified natural der p2 allergens for use in the treatment of house-dust mite allergy in mammals, like humans. The invention further pertains pharmaceutical compositions for allergy-specific immune therapy.
Citeq B.v.


Composition and application in baby lotion thereof
The present disclosure relates to a composition and application in baby lotion thereof. The composition consists of allantoin, grapefruit seed extract and garlic extract; the composition of the present invention effectively moisturizes the skin and reduces redness of skin allergy.
Shanghai Children's Nutrition Center Co., Ltd


Automatic decision support
Speech is transcribed to produce a transcript. At least some of the text in the transcript is encoded as data.
Mmodal Ip Llc


Methods of obtaining mononuclear blood cells and uses thereof
Methods of obtaining mononuclear blood cells are provided. Also provided are methods of using the obtained cells for treating diseases such as cancer, infectious disease, autoimmune disease, allergy, and graft rejection..
Biolinerx Ltd.


Sirp polypeptide compositions and methods of use
Provided herein are sirp-gamma, sirp-beta or sirp-beta2 decoy polypeptides for immunotherapy and/or treatment of cancer, anemia, transplant, asthma, allergy, auto-immune disease, and viral infection.. .
Ab Initio Biotherapeutics, Inc.


Idr peptide compositions and use thereof for treatment of th2-dysregulated inflammatory conditions
A composition for treating or preventing a th2-dysregulated inflammatory condition wherein the composition comprises a therapeutically effective amount of one or more idr peptides. Use of idr peptides or a composition comprising idr peptides for treating or preventing a th2-dysregulated inflammatory condition.
Suphatchatwong Innovation Co., Ltd.


Epigenetic markers for respiratory allergy
A method relates to epigenetic markers and their diagnostic and predictive value for respiratory allergy. The method can include assaying a test sample from the patient for a dna hypermethylation or hypomethylation of at least gli2 region, in which hypermethylation or hypomethylation of the gene region in the test sample indicates or predicts a respiratory allergy in the patient..
Vito Nv


Peptide derivative for regulating thymic stromal lymphoid protein-mediated signaling and pharmaceutical composition for preventing and treating allergy and asthma diseases comprising same

The present invention relates to a peptide derivative for regulating the thymic stromal lymphoid protein-mediated signaling and a pharmaceutical composition including the peptide derivative for preventing and treating allergy and asthma diseases and, more particularly, to a peptide derivative represented by chemical formula 1 and a pharmaceutical composition including the peptide derivative for preventing and treating allergy and asthma diseases. According to the present invention, provided are a peptide derivative capable of effectively inhibiting the formation of an inflammatory response of allergy and asthma diseases and a pharmaceutical composition including the peptide derivative.
Korea University Research And Business Foundation, Sejong Campus

Allergy vaccine composition

The present invention provides an allergy vaccine composition that is useful as a prophylactic or therapeutic agent for an allergic disease and can safely and effectively induce immune tolerance. The vaccine composition is to be administered to a human or animal with an allergic disease for the prevention or treatment of the allergic disease.
Nitto Denko Corporation

Method for examining food allergy and examination kit

An object of the present invention is to provide an examination method for simply and properly evaluating the risk of developing food allergy and seriousness of the symptoms of allergy. The present invention provides a method for examining food allergy in a subject, including a step of measuring urinary tetranor-pgdm amount of the subject..
The University Of Tokyo

Inhibition of gliadin peptides

Novel compounds and methods for the inhibition of biological barrier permeability and for the inhibition of peptide translocation across biological barriers are identified. Assays for determining modulators of biological barrier permeability and for peptide translocation across biological barriers are provided.
Alba Therapeutics Corporation

Prime-boost regimens involving administration of at least one mrna construct

The present invention relates to prime-boost regimens that involve the administration of at least one mrna construct, such as the use of such constructs in “boost” administration subsequently to “prime” administration of certain other antigenic composition(s). Such inventive regimens may, in particular, be useful for the induction of an immune response in a subject, and/or the vaccination of such subject against infection from one or more pathogens, and/or the treatment or prevention of one or more diseases or conditions, including a tumour or cancer, allergy or autoimmune conditions, and/or a disease or condition associated with infection from a pathogen.
Curevac Ag

Immunoconjugates for programming or reprogramming of cells

The conjugate compositions and methods are useful to elicit/augment an immune response to a tumor or microbial infection or to reduce the severity of autoimmunity, chronic inflammation, allergy, asthma, periodontal disease, and transplant rejection.. .
President And Fellows Of Harvard College

Therapeutic microbiota for the treatment and/or prevention of food allergy

Disclosed are methods and compositions for the prevention and treatment of food allergy. In particular, described herein are microbial consortia, including minimal microbial consortia, that can prevent and/or cure food allergy.
Children's Medical Center Corporation

Therapeutic microbiota for the treatment and/or prevention of food allergy

Disclosed are methods and compositions for the prevention and treatment of food allergy. In particular, described herein are microbial consortia, including minimal microbial consortia, that can prevent and/or cure food allergy.
Children's Medical Center Corporation

Therapeutic microbiota for the treatment and/or prevention of food allergy

Disclosed are methods and compositions for the prevention and treatment of food allergy. In particular, described herein are microbial consortia, including minimal microbial consortia, that can prevent and/or cure food allergy.
Children's Medical Center Corporation

Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor

The present invention provides methods for treating, preventing or reducing the severity of allergic reactions. The present invention also provides methods for enhancing the efficacy and/or safety of an allergen-specific immunotherapy (sit) regimen.
Regeneron Pharmaceuticals, Inc.

Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor

The present invention provides methods for treating, preventing or reducing the severity of allergic reactions. The present invention also provides methods for enhancing the efficacy and/or safety of an allergen-specific immunotherapy (sit) regimen.
Regeneron Pharmaceuticals, Inc.

Methods and reagents to treat autoimmune diseases and allergy

The present invention provides compositions for inducing immune tolerance and methods to modify antigen to treat disease such as autoimmune diseases and allergy. Disclosed are compositions, and related methods, comprising apc presentable antigens and immunosuppressants that provide tolerogenic immune responses specific to antigen.

Anti-human vista antibodies and use thereof

The invention provides antagonistic and agonistic anti-human vista antibodies and antibody fragments. These antagonist antibodies and antibody fragments may be used to inhibit or block vista's suppressive effects on t cell immunity and thereby promote t cell immunity.
Janssen Pharmaceuticals, Inc.

Novel compound useful for the treatement of degenerative and inflammatory diseases

A pyrazolopyridine compound according to formula i, able to inhibit jak is disclosed, as well as pharmaceutically acceptable salts, a solvate thereof, solvates of the pharmaceutically acceptable salts and biologically active metabolites thereof. The compound may be prepared as a pharmaceutical composition, and may be used for the treatment or prophylaxis of a variety of conditions in mammals including humans, and particularly, such conditions as may be associated with aberrant jak activity, including by way of non-limiting example, allergy, inflammatory conditions, autoimmune diseases, proliferative diseases, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6..

Treatment improving intestinal enviornment and intestinal tract barrier

Provided is a treatment method for improving intestinal environment and intestinal tract barrier, the treatment method including: a process of measuring a value of specific ig g to a food antigen inducing delayed food allergy of a patient of each food in a case where the patient has inflammation caused by local or systemic antigen-antibody reaction; a process of deriving an intestinal environment/barrier index that is scored ig g value based on the measured ig g value; and a process of performing treatment by combining removal of food with the high intestinal environment/barrier index and oral administration of a supplement which decreases the intestinal environment/barrier index.. .

Anti-il-25 antibodies and uses thereof

The present invention provides antibodies that bind to human interleukin-25 (il-25) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human il-25 with high affinity.
Regeneron Pharmaceuticals, Inc.

Novel vista-ig constructs and the use of vista-ig for treatment of autoimmune, allergic and inflammatory disorders

The present invention relates to a fusion proteins comprising regulatory t cell protein, vista (v-domain immunoglobulin suppressor of t cell activation (pd-l3) and an immunoglobulin protein (ig), preferably also containing a flexible linker intervening the vista and ig fc polypeptide. The invention also provides the use of vista polypeptides, multimeric vista polypeptides, vista-conjugates (e.g., vista-ig), and vista antagonists for the treatment of autoimmune disease, allergy, and inflammatory conditions, especially lupus, multiple sclerosis, psoriasis, psoriatic arthritis, multiple sclerosis, crohn's disease, inflammatory bowel disease and type 1 or type 2 diabetes..
King's College London

Bacterial compositions and methods of use thereof

The present invention relates to bacterial compositions and methods of use thereof. The bacterial compositions may include two or more bacteria of the genera faecalibacterium, lachnospira, veillonella or rothia.
The University Of British Columbia

Methods and compositions to reduce peanut-induced anaphylaxis

The present disclosure provides compositions comprising recombinant bacterial spores. The present disclosure is also directed to vaccine based compositions, which include recombinant bacterial spores that express ctb and a peanut protein(s) on their surfaces.

Devices and methods for applying antigens for allergy testing

Devices and methods for applying antigens for allergy testing. In certain embodiments the device comprises an elongated body comprising a first end and a second end and a curved lower surface extending between the first and second ends.

Combined fully organic high molecular material artificial knee joint

A combined fully organic high molecular material artificial knee joint, comprising a femur condyle (2), a tibia holder (4) and a tibia liner (3), the femur condyle (2) and the tibia holder (4) being formed by polyether ether ketone (peek) or derivatives thereof, and the tibia liner (3) being formed by ultra-high molecular weight polyethylene (uhmwpe). The tibia holder (4) comprises a platform (6) and a stable wing positioning portion (5) vertical thereto; upper and lower ends of the tibia liner (3) are jointed with the femur condyle (2) and the platform (6) respectively; the femur condyle (2) buffers a slide surface of the tibia liner (3); and the tibia holder (4) can finely move relative to a fixed surface of the tibia liner (3), and buffering of the femur condyle (2) against the slide surface of the tibia liner (3) matches fine movement of the tibia holder (4) relative to the tibia liner (3).
Jiangsu Okani Medical Technology Co., Ltd

Administration of plant expressed oral tolerance agents

Protein replacement therapy for patients with hemophilia or other inherited protein deficiencies is other complicated by pathogenic antibody responses, including antibodies that neutralize the therapeutic protein or that predispose to potentially life-threatening anaphylactic reactions by formation of ige. Using murine hemophilia b as a model, we have developed a prophylactic protocol against such responses that is non-invasive and does not include immune suppression or genetic manipulation of the patient's cells.
The Trustees Of The University Of Pennsylvania

Compositions and methods for characterizing and restoring gastrointestinal, skin, and nasal microbiota

The present invention relates to characterizing changes in mammalian bacterial gastrointestinal, cutaneous and nasal microbiota associated with antibiotic treatment and various disease conditions (such as asthma, allergy, obesity, metabolic syndrome, gastrointestinal reflux disease (gerd), eosinophilic esophagitis, gastro-esophageal junction adenocarcinomas (gejac), infections due to bacteria that are resistant to antibiotics, including methicillin-resistant staphylococcus aureus (mrsa), clostridium difficile, vancomycin-resistant enterococci, etc.) and related diagnostic and therapeutic methods. Therapeutic methods of the invention involve the use of live bacterial inoculants that are capable of restoring healthy mammalian bacterial gastrointestinal, skin, and nasal microbiota..
New York University

Early allergy detection, notification and management systems and methods

A watch-like early allergy detection, notification and management system is equipped with a motion detector as well as one or more physiological sensors to measure heart rate, skin color change, skin galvanic response, oxygen saturation and blood pressure to detect early symptoms of an allergic reaction. False alarms are reduced by simultaneously measuring ambient temperature and physical activity of the subject.

Dual input content processing

A content code is defined containing user content, and a corresponding profile code defining user context information. The profile code may be scanned and stored temporarily in a user device or elsewhere.
Mobilead

Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response

The invention provides novel immune regulatory oligonucleotides (iro) as antagonist of tlrs and methods of use thereof. These iros have unique sequences that inhibit or suppress tlr-mediated signaling in response to a tlr ligand or tlr agonist.
Idera Pharmaceuticals, Inc.

Baby food products containing allergenic proteins and methods of delivering same

Baby food products containing allergenic protein and methods of delivering the products are provided as a source of early introduction for prevention of food allergy in children. The product may be a solid or semi-solid product and includes an allergenic protein, one or more of a prebiotic or a probiotic, and a foodstuff.

Accelerator free and high filler load nitrile glove

A formulation of nitrile glove made from carboxylated acrylonitrile butadiene elastomer comprising an aluminum and zinc oxide compound as a crosslinker and a metal ion stabilizer without sulfur and accelerator for decreasing type iv allergy risk and providing a cost down method of increasing filler loading ability of carboxylated acrylonitrile butadiene latex.. .
Twolink Sdn Bhd

Use of prg4 as an anti-inflammatory agent

Disclosed herein are methods of using prg4 glycoprotein, also known as lubricin, to reduce, inhibit, or down-regulate pro-inflammatory pathways in patients at risk of or suffering from an inflammatory response or allergy symptom through cd44 antagonization, regulating pro-inflammatory cytokine production, inhibiting nf-κb translocation and/or facilitating removal of inflammation-inducing cellular or matrix debris or allergens.. .
Rhode Island Hospital, A Lifespan Partner

Methods for allergy diagnosis

Provided herein are improved methods for diagnosing allergy in a subject using designed ankyrin repeat proteins (“darpins”), and kits for use in such methods. Also provided herein are novel darpins and methods of use thereof..
Immunovent, Llc

Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Useful in the prophylaxis and/or treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving degradation and/or disruption of cartilage homeostasis, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6 or interferons.. .

Allergy skin test applicator

An allergy testing kit contains a plurality of allergy testing applicators, an allergy testing tray and a plurality of allergen bottles each containing an allergen. Each of the applicators contains an elongated handle, a plurality of arms extending from the elongated handle and disposed in an asymmetrical configuration, and a plurality of legs with tines extending from each of the arms.

Baked lotus root cake, solid food using lotus root powder, and methods for manufacturing same

To provide a baked lotus root cake and a solid food that comprises, as a main ingredient, a lotus root powder with little risk of allergy. A baked lotus root cake characterized by being prepared by kneading under heating a mixture, said mixture comprising a lotus root powder as a main ingredient, and heating and pressurizing the kneaded matter thus obtained to give a thin sheet-shaped baked product.
Lotusweets Co., Ltd.

Method and use in allergy testing

There is provided a method for use in determining whether a subject is allergic to a substance. The method comprises: receiving a first set of spatially distributed light intensity values covering a skin region of the subject including a location at which the substance has been applied; wherein the light intensity values in the first set are intensities of visible light; receiving a second set of spatially distributed light intensity values covering the skin region, wherein the light intensity values in the second set are intensities of infrared, ir, light; generating a first spatial distribution of photoplethysmogram, ppg, pulse amplitudes based on the first set of light intensity values; generating a second spatial distribution of ppg pulse amplitudes based on the second set of light intensity values; comparing the first spatial distribution to the second spatial distribution, and to the location at which the substance has been applied; and outputting an indication of whether the subject is experiencing an allergic reaction to the substance based on the comparing..
Koninklijke Philips N.v.

Monoclonal antibody against muramyl peptides in prevention and treatment of immune-mediated diseases

Disclosed are methods of treating an autoimmune or inflammatory disease using a composition comprising an isolated antibody or an antigen-binding fragment or variant thereof that is capable of binding to muramyl peptide, derivative, analog or salt thereof, wherein said muramyl peptide comprises muramic acid and an amino acid selected from the group consisting of alanine, isoglutamine, glutamic acid and a salt thereof. In one preferred embodiment, the composition can comprise of the isolated antibody or an antigen-binding fragment and one or more therapeutic agents such as tumor necrosis factor (tnf) inhibitor.
Agency For Science, Technology And Research

Allergy treatment kit

A portable emergency treatment kit for allergic and anaphylactic reactions. The kit comprises a carry case comprising a first panel and a second panel detachably connected together by a fastening member such as a zipper unit.

Vista regulatory t cell mediator protein, vista binding agents and use thereof

The present invention relates to a novel regulatory t cell protein. This protein, designated pd-l3 or vista resembles members of the pd-l1 family, identified a novel and structurally-distinct, ig-superfamily inhibitory ligand, whose extra-cellular domain bears homology to the b7 family ligand pd-l1.
The Trustees Of Dartmouth College

Treatment of allergies and autoimmune diseases

The present disclosure provides a method of treating allergies and autoimmune diseases using microsystem acupuncture. Methods provided herein for treating allergies and autoimmune diseases using microsystem acupuncture involving a novel allergy zone.

Topical use of prg4 for treatment of allergy and symptoms of inflammation

Disclosed are methods involving the therapeutic use of human prg4 (prg4) protein, to ameliorate the symptoms associated with allergies and/or respiratory infections.. .

Aerosol composition for the prevention of symptoms of metal induced allergy and a synthesizing the same

The embodiments herein disclose hypoallergenic, metal surface sealant clear aerosol composition to be used on metals (specifically jewelry) to prevent skin allergies and the process of tarnishing of metal. The method of synthesizing hypoallergenic metal surface sealant clear aerosol composition comprises the following steps.

Anti-human vista antibodies and use thereof

The invention provides agonistic anti-human vista antibodies and antibody fragments. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic vista's suppressive effects on t cell immunity and thereby suppress t cell immunity.
The Trustees Of Dartmouth College

Anti-human vista antibodies and use thereof

The invention provides agonistic anti-human vista antibodies and antibody fragments. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic vista's suppressive effects on t cell immunity and thereby suppress t cell immunity.
Immunext, Inc.

Anti-human vista antibodies and use thereof

The invention provides agonistic anti-human vista antibodies and antibody fragments. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic vista's suppressive effects on t cell immunity and thereby suppress t cell immunity.
Immunext, Inc.

Anti-human vista antibodies and use thereof

The invention provides agonistic anti-human vista antibodies and antibody fragments. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic vista's suppressive effects on t cell immunity and thereby suppress t cell immunity.
Immunext, Inc.

Anti-human vista antibodies and use thereof

The invention provides agonistic anti-human vista antibodies and antibody fragments. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic vista's suppressive effects on t cell immunity and thereby suppress t cell immunity.
The Trustees Of Dartmouth College

Anti-human vista antibodies and use thereof

The invention provides agonistic anti-human vista antibodies and antibody fragments. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic vista's suppressive effects on t cell immunity and thereby suppress t cell immunity.
Immunext, Inc.

Glycotargeting therapeutics

Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent.. .

Diamino-pyridine, pyrimidine, and pyridazine modulators of the histamine h4 receptor

Diamino-pyridine, pyrimidine and pyridazine compounds which may be used as h4 receptor modulators, and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by h4 receptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.. .

Methods and compositions involving recombinant hypoallergens

This disclosure describes recombinant hypoallergens and methods of treating allergy that involve administering a recombinant hypoallergen to a subject. Generally, the recombinant hypoallergen includes at least one amino acid modification compared to a corresponding wildtype allergen.

Immune system stimulating nutrition

Disclosed is a nutritional composition comprising a combination of non-digestible oligosaccharides and a product obtained by incubating an aqueous substrate by bifidobacteria and optionally a product obtained by incubating an aqueous substrate by s. Thermophilus.

Benzazepine sulfonamide compounds

Wherein r4 or r5 is —so2—nr7r8 and r1 to r8 and y are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are tlr agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases..

Composition for the prevention and/or treatment of allergy symptoms

The present invention relates to a pharmaceutical composition or a food supplement composition and use thereof in the prevention and/or treatment of allergy symptoms, preferably allergic rhinitis and/or allergic conjunctivitis symptoms. In particular, the composition according to the invention comprises at least one slow release component comprising quercetin and at least one fast release component comprising an extract from perilla frutescens or a constituent thereof selected from luteolin, rosmarinic acid, apigenin, catechina, ferulic acid, caffeic acid or mixtures thereof, the invention further comprises the use of the composition in the prevention and/or treatment of allergy symptoms, preferably allergic rhinitis and/or allergic conjunctivitis symptoms..
Ntc S.r.l.

. .

Nasal stimulation for rhinitis, nasal congestion, and ocular allergies

Described here are devices, systems, and methods for treating one or more conditions, such as allergic rhinitis, non-allergic rhinitis, nasal congestion, ocular allergy, and/or symptoms associated with these conditions, by providing stimulation to nasal or sinus tissue. In some variations, the handheld devices may have a stimulator body and a stimulator probe having one or more nasal insertion prongs, and the nasal insertion prongs may be configured to deliver an electrical stimulus to the tissue..
Oculeve, Inc.

Methods and kits for screening transplant recipients and candidates

Methods and kits are provided for determining of immunoglobulin isotypes and subclasses in a subject. In general the subject is a human who is a transplant candidate recipient or recipient, has allergies, or has an autoimmune disease.
National Institute Of Transplantation Foundation

Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response

The invention provides novel immune regulatory oligonucleotides (iro) as antagonist of tlrs and methods of use thereof. These iros have unique sequences that inhibit or suppress tlr-mediated signaling in response to a tlr ligand or tlr agonist.
Idera Pharmaceuticals, Inc.

Antibody therapeutics that bind ctla4

There is disclosed compositions and methods relating to or derived from anti-ctla4 antibodies. More specifically, there is disclosed fully human antibodies that bind ctla4, ctla4-antibody binding fragments and derivatives of such antibodies, and ctla4-binding polypeptides comprising such fragments.
Sorrento Therapeutics, Inc.

An anti-cd45rc antibody for use as drug

The invention relates to an isolated anti-cd45rc antibody for use in preventing or treating transplant rejection, autoimmune diseases, unwanted immune responses against proteins expressed in the course of gene therapy and/or therapeutic proteins, allergy as well as lymphoma or cancer which are associated with cd45rc+ cells. The invention relates to an isolated anti-cd45rc antibody for use in expanding and/or potentiating regulatory t cells..
UniversitÉ De Nantes

Nanoparticles for treatment of allergy

The present invention encompasses the surprising finding that nanoparticle compositions can have beneficial effects on allergy even when prepared without a known specific allergy therapeutic. The present invention provides such nanoparticle compositions.
Allertein Therapeutics, Llc

Novel allergen

The invention relates to a novel horse allergen consisting of a heterodimeric protein having a first peptide chain and a second peptide chain together having an overall sequence identity of at least 70% with the combined sequences of seq id no:3 and seq id no: 4, as well as a single chain protein having an overall sequence identity of at least 70%, such as 75%, 80%, 85%, 90%, 95%, or 98%, with the combined amino acid sequences according to seq id no: 3 and seq id no: 4. The invention further relates to the use of the protein in methods of diagnosis and therapy of type i allergy, and kits and compositions for use in such methods..
Phadia Ab

Peptides, reagents and methods for detecting food allergy

Provided are peptide biomarkers for diagnosis of allergy, monitoring development of clinical tolerance in an allergic individual, and predicting whether an allergic subject is likely to develop clinical or natural tolerance over time. The invention also relates to diagnostic methods and diagnostic kits employing the peptide biomarkers..
Icahn School Of Medicine At Mount Sinai

Nutritional compositions containing dietary butyrate and uses thereof

Provided are nutritional compositions including a component for stimulating butyrate production in the human gut and/or dietary butyrate. Further disclosed are methods of reducing allergic reaction and promoting tolerance to cow's milk allergy in a pediatric subject by providing said nutritional compositions to a target subject..
Mead Johnson Nutrition Company

Application of green tea and its derivatives, composition for use therewith, veterinary pharmaceutical formulation and kit of parts

Use of a composition comprising the administration of crushed leaves of green tea in the treatment of type i allergy. The composition may especially be enriched with substances extracted from green tea, preferably catechin or a derivative thereof.

Allergy-inhibiting sea grape extract, its preparation method and application thereof

Present invention relates to an allergy-inhibiting sea grape extract, its preparation method and thereof. The preparation method includes following steps: the sea grape is blended in distilled water in the weight ratio of 1:1˜20, mix thoroughly, stir at 20-100° c.
East Green Bio Corporation

Prevention or treatment of food allergy in infants and toddlers

The invention pertains to the use of a non-digestible oligosaccharide in the manufacture of a composition for providing nutrition to an infant suffering from an increased risk of food allergy, preferably whey protein allergy; and/or reducing the risk of occurrence of or preventing whey protein allergy in an infant suffering from an increased risk of food allergy, particularly whey protein allergy. The infant is preferably at increased risk of trichothecene mycotoxin exposure, for instance by eating a lot of cereals..
N.v. Nutricia

An isolated interleukin-34 polypeptide for use in preventing transplant rejection and treating autoimmune diseases

The invention relates to an isolated interleukin-34 (il-34) polypeptide for use in preventing or treating graft rejection, autoimmune disease, unwanted immune response against therapeutic proteins and allergy. The invention also provides an in vitro method for determining whether a patient is at risk of transplant rejection, autoimmune diseases, unwanted immune response against therapeutic proteins or allergies, comprising a step of determining the expression level of il-34 in a biological sample obtained from said patient, wherein the presence of il-34 is indicative of a reduced risk of transplant rejection, autoimmune diseases, unwanted immune response against therapeutic proteins or allergies..
UniversitÉ De Nantes

Device and the diagnosis of gastrointestinal allergy

A method and device for the diagnosis of gastrointestinal allergy. The method and the device expose a surface to at least one antigen at a fixed depth.

Dd1alpha receptor and uses thereof in immune disorders

Described herein are methods and compositions for treatment of immune-related diseases or disorders by modulating dd1α activity, alone or in combination with modulation of pd-1 activity. In some embodiments, the methods and compositions described herein are directed to treatment of cancer and/or infections (e.g., bacterial infection, and/or fungal infection).
The General Hospital Corporation

Allergy service management portal

Aspects of the present disclosure involve systems, programs, and methods for an allergy management system (ams). In general, the ams provides a system through which a practitioner or other user may manage allergy-related care for one or more patients.
Allergy Solutions, Inc.

Compositions and methods relating to the treatment of diseases

The present invention relates to compositions and methods for promoting the induction of a cell-mediated immune response (such as that mediated by th1 cells) and the suppression of a humoral or allergic immune response (such as that mediated by th2 and th17 cells). In particular, the invention relates to compositions and methods for preventing or treating allergy, such as food allergy, and associated allergic diseases, and conditions where an exaggerated th17 response plays a detrimental role.
Alfacyte Ltd

Compositions and methods for modulation of rorgammat functions

The present invention relates to expression of rorγt in cells and tissues and the effect of expression of this gene on proliferation of specific immune cells and in promotion of immune cell aggregates and in induction of il17 producing cells. Furthermore, the invention relates to methods and agents that may decrease function of the gene product (the protein) or expression of this gene in individuals experiencing an inflammatory condition, an autoimmune disease or a food allergy, or any other condition whereby it is desirable to inhibit an immune response.

Idr peptide compositions and use thereof for treatment of th2-dysregulated inflammatory conditions

A composition for treating or preventing a th2-dysregulated inflammatory condition wherein the composition comprises a therapeutically effective amount of one or more idr peptides. Use of idr peptides or a composition comprising idr peptides for treating or preventing a th2-dysregulated inflammatory condition.
University Of Manitoba

Synergistic nutritional compositions and uses thereof

Provided are nutritional compositions comprising a combination of a probiotic, dietary butyrate and/or a component for stimulating butyrate production in the human gut. Further disclosed are methods of accelerating tolerance to cow's milk allergy in a pediatric subject by providing said nutritional compositions to a target subject..
Mead Johnson Nutrition Company

Peptide for vaccine

The present invention relates to compositions comprising peptides for preventing or treating allergy to house dust mites, and in particular to optimal combinations of peptides for preventing or treating said allergy.. .
Circassia Limited

Mobile chamber apparatuses and related methods

A mobile chamber apparatus includes a support structure of inflatable support members, and a chamber assembly. The inflatable support members may include transverse and upright sections.
Inflamax Research Inc.

Method for risk assessment of allergic reaction

A method for assessing the risk of an individual developing and immunoglobulin-mediated reaction to one or more allergens increases the specificity of allergy diagnosis and evaluates the specificity of a given allergenic substance. The method may be utilized in in vitro allergy tests, apparatuses, and devices to increase the accuracy and precision of test results.
Excelsior Bio-system Incorporation

Human fgfr2b extracellular domain and nucleic acid for coding same

Provided are wild-type, s252w mutant-type, and p253r mutant-type fgfr2b extracellular segments and truncated proteins thereof, coding genes of the foregoing proteins, a recombinant vector comprising the genes, a host cell, a method for preparing the proteins, and a fusion protein of the proteins and an fc segment. Also provided are applications of the proteins and a composition comprising the proteins in treating eczema, acne, psoriasis, skin allergy, seborrheic dermatitis, or seborrheic alopecia..
Guangzhou Shenglu Biotech Limited Company

Compound of glycosaminoglycan and its fabrication method as well as application

The present invention is related to a compound conjugating a drug with a glycosaminoglycan, such as hyaluronic acid (ha), where the drug is useful for the treatment of diseases such as inflammation, auto-immune disease, allergy, infection and preferably cancer. The conjugated compound of the present invention can increase the concentration of drug at the specific site of disease by an interaction of the glycosaminoglycan used as target drug delivery carrier and the cd44 cell surface receptor, then enhancing the therapeutic efficacy and reducing the systemic side effect of the site-delivered drug..
Holy Stone Healthcare Co., Ltd.

Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response

The invention provides novel immune regulatory oligonucleotides (iro) as antagonist of tlrs and methods of use thereof. These iros have unique sequences that inhibit or suppress tlr-mediated signaling in response to a tlr ligand or tlr agonist.

Allergy warning and protection system and method

An allergy warning and protection system and method to proactively warn a user and protect a dependent individual, such as a child, suffering from allergies. The system comprises a beacon housed within a wearable, such as a bracelet, that is worn by the dependent.

Humanized anti-ige antibodies that crosslink cd23 on b lymphocytes but do not sensitize mast cells

A novel humanized anti-ige antibody is disclosed. The antibody is capable of binding to free ige, membrane-bound ige on b lymphocytes, ige bound by cd23, but not to ige bound by high-affinity ige.fc receptor on mast cells.
Academia Sinica

Anti-human chemokine (c-c motif) receptor 4 immunotoxins

Anti-human chemokine (c—c motif) receptor 4 immunotoxins and methods of use thereof, e.g., for depleting tregs as an immunotherapy for the treatment of cancer; for the treatment of cancers associated with ccr4+ tumor cells such as skin homing cutaneous t cell lymphoma, adult t cell leukemia/lymphoma, and acute t-cell lymphoblastic leukemia; and for the depletion of cccr4+ th2 cells for the treatment of allergy-related conditions such as asthma.. .
The General Hospital Corporation

Allergy inhibitor compositions and kits and methods of using the same

Compositions, methods, and kits for inhibiting an allergic response against an allergenic protein are disclosed. Compositions, methods and kits for inhibiting an allergic response against a flea allergenic protein; a feline allergenic protein; a canine allergenic protein; a dust mite allergenic protein; a peanut allergenic protein; a japanese cedar allergenic protein; and a blomia tropicalis allergenic protein are disclosed..
Plant Genetics International Limited

Benzimidazole derivatives as pi3 kinase inhibitors

This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3′ oh kinase family (hereinafter pi3 kinases), suitably, pi3kα, pi3kδ, pi3kβ, and/or pi3kγ. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries.
Glaxosmithkline Llc

Menu displaying method, menu displaying device

The server receives allergy information. The server controls whether a photograph or an illustration of a product is not displayed in correlation with a name of the product to be displayed on the basis of whether the product includes an allergen corresponding to the allergy information..
Fujitsu Limited

Method of genetically altering and producing allergy free cats

A transgenic cat with a phenotype characterized by the substantial absence of the major cat allergen, fel d i. The phenotype is conferred in the transgenic cat by disrupting the coding sequence of the target gene with a specialized construct.

Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring

Described herein are methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring based on the level of tigit, flg2 and/or il-33 expression and/or activity. In some embodiments, the methods and compositions described herein are directed to treatment and/or therapy monitoring of cancer and/or infections (e.g., chronic viral infection, intracellular and/or extracellular bacterial infection, and/or fungal infection).
The Brigham And Women's Hospital, Inc.

Met e 1 tropomyosin variants for use in allergen-specific immunotherapy

The present invention provides isolated met e 1 polypeptides and nucleic acids encoding the isolated polypeptides that can prevent and/or alleviate an allergic response to shellfish tropomyosin. The polypeptides are based on the shrimp tropomyosin met e 1 protein and have been modified to act as hypoallergens.
The Regents Of The University Of California

Device with integrated allergy testing

A coupler for indicating the presence of a substance in blood is disclosed. The coupler includes a housing and a test strip.
Teleflex Medical Incorporated

Dna aptamers specific to cd200r1 and their therapeutic uses

Disclosed are short dna aptamers that selectively recognize cd200r1, a protein expressed on the surface of myeloid and lymphoid cells that delivers immune inhibitory signals to modulate inflammation when engaged with its ligand, cd200. Also disclosed is the use of said aptamers as therapeutic agents, for the purpose of decreasing inflammatory response; treatment of spinal cord injury; treatment of an immune related disease such as arthritis, allergy, infection; as a course of treatment during or after transplantation; or for treatment of an autoimmune disorders such as systemic lupus erythematosus, parkinson's disease, or multiple sclerosis..
D5pharma Inc.

Inhibition of gliadin peptides

Novel compounds and methods for the inhibition of biological barrier permeability and for the inhibition of peptide translocation across biological barriers are identified. Assays for determining modulators of biological barrier permeability and for peptide translocation across biological barriers are provided.
Alba Therapeutics Corporation

Methods and compositions for treating allergy and inflammatory diseases

Described herein are therapeutic approaches with immune modifiers of the th2 pathway for the treatment of allergic and inflammatory diseases. Aspects of the disclosure relate to methods for decreasing th2-type cell responses in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an anti-dectin-1 antibody or antigen binding fragment thereof operatively linked to a tlr agonist..
Baylor Research Institute

Chromatographic immune assay for the detection of allergic sensitivities

An apparatus is provided comprising a conjugate pad, the conjugate pad contains igg antibodies capable of detecting human ige antibodies and a nitrocellulose membrane strip including a test zone (t) and a control zone (c), wherein the test zone (t) is coated with a relevant purified antigen cognate to a specific ige of interest, wherein the coated test zone of the nitrocellulose membrane strip is configured to provide a visual indication of the presence of an anti-antigen ige antibody in a sample above a predetermined threshold.. .
Globallergy, Llc

Allergen for prophylactic treatment of allergy

A composition comprising at least one first allergen, which is a respiratory allergen belonging to a first biological source material group, for use in prophylactic treatment of allergy to at least one second allergen, which is selected from the group consisting of a respiratory and a venomous allergen belonging to a second biological source material group and a food allergen of a food composition, in a subject, wherein the subject has not developed any clinical symptoms of allergy to the first allergen and to the second allergen, and wherein the first and second biological source material groups are not the same.. .
Alk-abellÓ A/s

Gene delivery stent using titanium oxide thin film coating and fabricating the same

The present invention relates to a gene delivery stent using titanium oxide thin film coating and a method for fabricating the gene delivery stent. The gene delivery stent according to the present invention may be loaded with a drug having anti-inflammatory and anti-thrombotic effects and simultaneously deliver a gene capable of inhibiting proliferation of vascular smooth muscle cells.
Chonnam National University Hospital

Allergy testing device and testing for allergies

An allergy testing system comprises a skin test device having a grip portion for holding the device. One or more legs extend from the grip, and each leg is oriented to interact with a well containing a potential allergen.
Lincoln Diagnostics, Inc.

Treatments of ocular allergy with alcaftadine

Compositions, kits and methods for the treatment or prevention of ocular allergies and inflammation and the symptoms thereof comprising alcaftadine or a pharmaceutically acceptable salt thereof.. .
Vistakon Pharmaceuticals, Llc

Allergen exposure system comprising a chamber for mixing air and allergens, which is separated from the exposure room that accommodates the patients

An allergen exposure system includes a mixing chamber, delimited by walls and distinct from the air inlet duct and from the exposure room in which the patients are situated. A mixing between a stream of allergen particles from an allergen injection device and a flow of air devoid of allergens which has passed through a filtration device, occurs through a phenomenon of microturbulence in this mixing chamber which forms a widening with respect to the air inlet duct and makes it possible to obtain a flow of air laden with allergen particles which is injected into the exposure room through at least one diffusion outlet so that it can be inhaled by the patients.
Alyatec

Method for synthesis of a biopolymer derivative, a biopolymer derivative and its use

The invention relates to a method of synthesis of a biopolymer derivative, preferably a chitosan derivative, comprising the formation of a peptide bond. The invention also relates to the biopolymer derivative, and use of the biopolymer derivative, preferably a chitosan derivative.
Instytut Biochemii I Biofizyki Polskiej Akademii Nauk

Treating infection

The present invention relates to surfactant protein d (sp-d) or nucleic acids encoding sp-d or variants thereof such as surfactant protein a or mannan binding lectin for use in the treatment and/or prevention of a parasitic infection. Methods for determining the presence of a parasitic infection by determining levels of sp-d in a sample are also disclosed.
University Of Cape Town

Method of treating inflammation, allergy and asthma with a purified extract (atc1) isolated from pseudolysimachion rotundum var. subintegrum containing abundant amount of active ingredient

The present invention relates to inventive novel industrialized method for preparing purified extract containing more abundant active ingredients such as catalpol derivatives from the extract of pseudolysimachion rotundum var subintegrum than that prepared by the conventional preparation method disclosed in the prior art and the therapeutics or functional health food comprising the purified extract for treating and preventing inflammatory, allergic or asthmatic disease. The purified extract showed more potent anti-inflammatory, anti-allergy and anti-asthma activity than that prepared by the conventional preparation method disclosed in the prior art through various in vivo tests such as inhibition test on the reproduction of eosinophil, the release of immunoglobulin and inflammatory chemokines in plasma and bronchoalveolar fluid as well as the suppression of airway hyperresponsiveness and goblet cell hyperplasia in a ova-sensitized/challenged mouse model..
Korea Research Institute Of Bioscience And Biotechnology

Method of treating inflammation, allergy and asthma with a purified extract (atc2) isolated from pseudolysimachion rotundum var. subintegrum containing abundant amount of active ingredient

The present invention relates to inventive novel industrialized method for preparing purified extract containing more abundant active ingredients such as catalpol derivatives from the extract of pseudolysimachion rotundum var subintegrum than that prepared by the conventional preparation method disclosed in the prior art and the therapeutics or functional health food comprising the purified extract for treating and preventing inflammatory, allergic or asthmatic disease. The purified extract showed more potent anti-inflammatory, anti-allergy and anti-asthma activity than that prepared by the conventional preparation method disclosed in the prior art through various in vivo tests such as inhibition test on the reproduction of eosinophil, the release of immunoglobulin and inflammatory chemokines in plasma and bronchoalveolar fluid as well as the suppression of airway hyperresponsiveness and goblet cell hyperplasia in a ova-sensitized/challenged mouse model..
Korea Research Institute Of Bioscience And Technology

Methods of measuring antigen-specific t cells

Provided herein are methods and kits for assaying antigen-specific t cell responses, such as rare autoantigen-specific t cell responses, by measuring a level of ip-10 in a sample from a subject having or suspected of having an autoimmune disease, an allergy, an infectious disease or condition, or an adverse immune condition caused by administration of an isolated, recombinant or synthetic protein or peptide. Also provided herein are methods and kits for assaying a t cell response to an antigen peptide, such as an islet autoantigen peptide, such as measuring a t cell response to at least one antigen peptide, such as an islet autoantigen peptide, in a sample from a subject, such as one having or suspected of having type 1 diabetes (tid), celiac disease or both..
Immusant, Inc.

Individually customized allergy cream for individual patient profile

A method for delivering an immunomodulator to a patient includes providing a bottle of concentrated immunomodulator extract; progressively diluting the antigen extract in sterile bottles; selecting a prescribed amount from a desired one of the dilution bottles; providing a viscous encapsulation material that is able to introduce antigens contained therein through the skin of a patient; introducing one or more doses of the selected prescribed amount of diluted immunomodulator into the viscous encapsulation material; disposing a prescribed amount of viscous encapsulation material containing the introduced diluted immunomodulator therein within a container that is able to dispense such viscous encapsulation material containing the introduced diluted immunomodulator; dispensing from the container the amount of viscous encapsulation material containing the diluted immunomodulator in an amount equal to a single dose; and applying the dispensed viscous encapsulation material containing the introduced diluted immunomodulator to the skin by the patient or a medical professional.. .
Roca Medical Ltd.

Implantable device for automatic delivery of medication for allergic reactions

Apparatus, implanted subcutaneously or in muscle, fat, joint spaces, or body cavities of any type, detects and responds to an allergic and/or anaphylactic reaction. Detection is carried out by monitoring the levels of biomarker molecules that indicate the occurrence of an allergic and/or anaphylactic reaction, such as: histamine, leukotrienes, prostaglandins, cytokines, tryptase, fc-ε-ri complexes, anaphylatoxin c3a, chymase, carboxypeptidase a, platelet-activating factor8, other mast cell degranulation byproducts, or other basophil activation compounds.

Compositions and methods for treating itching, gingivostomatitis, and demodectic mange

Provided are methods for treating itching caused by allergy, include itching associated with parasite-mediated inflammation (e.g., demodicosis, stomatitis, dermatophytosis, etc.), comprising administration to a mammalian subject in need thereof a therapeutically effective amount of a heat-treated, fractionated thymus extract composition (e.g., thyex-1-6a and -6b compositions, comprising proteins or polypeptides having molecular weights in the range of 3.5 kda to 30 kda), in combination with or formulated with colostrum, to provide for reducing itching in the subject. Combination or adjunctive therapies comprising administration of a heat-treated, fractionated thymus extract composition in combination with or formulated with colostrum, and including at least one additional anti-parasitic, anti-bacterial, anti-fungal, anti-viral agent, or homeopathic agent are also provided.
Cmi Research Management, Llc

Medical software platform

A medical system is disclosed for retrieving and recording information from a patient and generating an efficient and effective clinical report encompassing the relevant data for a practitioner's review. The system may also include one or more communication paths for receiving additional information such as from patient wearables, environmental sensors, medication dispensers, whether sources, allergy sources, and other geographic relevant environmental conditions, contaminants, conditions, traffic congestion, etc..
Victaire Inc.

Nkt cell ligands and methods of use

Alpha-glycosylceramide compounds capable of activating nkt cells and compositions thereof are disclosed. Methods for activating nkt cells, methods of stimulating an immune response in a subject, and methods of treating cancer, infectious diseases, autoimmune diseases and disorders, or allergy diseases or disorders with the compounds and compositions are also disclosed..
Brigham Young Unversity

Purified extract isolated from pseudolysimachion rotundum var. subintegrum containing abundant amount of active ingredient, the preparation thereof, and the composition comprising the same as an active ingredient for preventing or treating inflammation, allergy and asthma

The present invention relates to inventive novel industrialized method for preparing purified extract containing more abundant active ingredients such as catalpol derivatives from the extract of pseudolysimachion rotundum var subintegrum than that prepared by the conventional preparation method disclosed in the prior art and the therapeutics or functional health food comprising the purified extract for treating and preventing inflammatory, allergic or asthmatic disease. The purified extract showed more potent anti-inflammatory, anti-allergy and anti-asthma activity than that prepared by the conventional preparation method disclosed in the prior art through various in vivo tests such as inhibition test on the reproduction of eosinophil, the release of immunoglobulin and inflammatory chemokines in plasma and bronchoalveolar fluid as well as the suppression of airway hyperresponsiveness and goblet cell hyperplasia in a ova-sensitized/challenged mouse model..
Korea Research Institute Of Bioscience And Biotechnology

Method for manufacturing fermented food composition

According to a manufacturing method of the present invention, class 2 food allergens can be decomposed even if a protease is not used, and thus a manufacturing cost is inexpensive, and a food composition having a reduced content of class 2 food allergens can be provided without using salt water which has an effect on the taste. The fermented food composition, obtained by the manufacturing method of the present invention, has a sufficiently reduced content of the class 2 food allergens, and thus even those who contracts pollinosis or latex allergy can safely take it.
Kaneka Corporation

Allergy preventing dosage controlled food packets

A kit of individual packets of food containing a dosage amount of an allergen. The kit has a plurality of packets associated with each other and containing a carrier food in each packet and an allergen so arranged that the respective allergen quantity in each successive packet is larger than in the previous packet.

Interleukin-2 for treating food allergy

The present invention relates to the use of interleukin-2 (il-2) for treating a food allergy, either by inducing non-specific tolerance against food allergens, or in a desensitization protocol, in combination with a food allergen.. .
Centre National De La Recherche Scientifique

Compositions and methods for combination ingredient delivery

Described herein are compositions, methods, and devices for relief of a cough, cold, sore throat, or allergy, or a related symptom. Also described herein are compositions, methods, and devices for the prevention, treatment and/or amelioration of a digestive illness or digestive discomfort, or a related symptom of either..
The Fix, Llc

Vaccine comprising amb a 1 peptides for use in the treatment of ragweed allergy

The present invention relates to compositions for preventing or treating allergy to ragweed by tolerisation. The compositions are based on combinations of peptide fragments derived from the major allergen in ragweed pollen, amb a 1.
Circassia Limited

Screening the identification of agents capable of activating cd4+cd25+ regulatory t-cells through interactions with the hiv-1 gp120 binding site on cd4

The present invention relates specific activation of a regulatory t cell via a specific cd4 epitope and uses thereof, e.g. For the treatment of an autoimmune disease or an allergy or asthma or graft rejection or tolerance induction..
Tcf Gmbh

Use of escin

The present invention provides the use of escin for the manufacture of a pharmaceutical preparation for the treatment diseases mediated or caused by activated granulocytes, preferably a type i or type iii allergy or septic shock.. .
Marinomed Biotechnologie Gmbh

Benzazepine dicarboxamide compounds

Wherein r1 to r4 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are tlr agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases..

Glycotargeting therapeutics

Several embodiments of the present disclosure relate to glycotargeting therapeutics that are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent. In several embodiments, the compositions are configured to target the liver and deliver antigens to which tolerance is desired.
École Polytechnique Fédérale De Lausanne (epfl)

Allergy skin test devices

An allergy skin test device can include a support strip having a top and bottom face. An allergen can be applied to an area of the bottom face forming an allergen portion.
Rememdia Lc

Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Useful in the prophylaxis and/or treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving degradation and/or disruption of cartilage homeostasis, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6 or interferons.. .

Novel immunotherapeutic composition and uses thereof

The present invention relates generally to an immunotherapeutic composition. More particularly, the present invention relates to an immunotherapeutic composition which interacts immunologically with t lymphocytes in subjects having peanut allergy or allergy to other tree nuts.
Aravax Pty Ltd

Newly identified peptides for use in the induction of oral tolerance in young mammals

The invention relates to newly identified peptides of that are capable of inducing tolerance to cow's milk, especially to β-lactoglobulin. The peptides may be administered to mammals, especially to young infants who are at risk of allergy to cow's milk proteins, to induce oral tolerance to cow's milk; they may also be administered to children or adults who are allergic to cow's milk to allow “desensitization” towards the allergenic milk proteins, especially β-lactoglobulin, to occur.
Nestec S.a.

C1q as a therapeutic agent of allergy and/or asthma

The present invention concerns c1q for use for treating allergy and/or asthma. The invention also relates to a pharmaceutical composition comprising c1q and at least one allergen and to products comprising c1q and at least one allergen as a combined preparation for use for treating allergy and/or asthma..
Stallergenes

Contact thermo-optical structure and its application for non-invasive imaging of histamine-induced hyperthermal subcutaneous reaction magnitude in cutaneous allergic reaction, recording device and allergic reaction diagnosis

A method of diagnosing allergy according to the invention comprises the steps of stimulation, measurement and comparison. The stimulation step includes at least exposition of a first region of patient's skin to a histamine solution, exposition of a second region of patient's skin to a neutral solution and exposition of a third region of patient's skin to a test substance.

Novel histamine releaser contained in human sweat

Provided are a sweat allergy antigen, an antibody capable of binding to the antigen specifically, and others, which are produced utilizing a microorganism-originated protein that exists in sweat allergy patient in a dissolved state or a partial peptide of the protein.. .
Hiroshima University

Mimotopes for use in immunotherapy for shellfish and/or arthropod allergy

The present invention provides isolated peptides and nucleic acids encoding the isolated peptides that can modify a subject's immune response to tropomyosin. The isolated peptides correspond to peptide epitope mimics that are based on an invertebrate tropomyosin allergen, e.g., the shrimp tropomyosin met e 1.
The Chinese University Of Hong Kong

Effector-deficient anti-cd32a antibodies

Effector-deficient anti-cd32a monoclonal antibodies are encompassed, as are method and uses for treating cd32a-mediated diseases and disorders, including, thrombocytopenia, allergy, hemostatic disorders, immune, inflammatory, and autoimmune disorders.. .
Adventist Health System/sunbelt Inc.

Air purification method and apparatus

An air purification method for use in an apparatus is provided. The air purification method includes: acquiring plant information associated with one or more plants located in a target detection region; determining, based on the plant information and predetermined reference plant information of an allergy-causing plant, that the target detection region contains the allergy-causing plant and the allergy-causing plant is in a blooming state; and in response to the determining, enabling an air purification function of an air purification device..
Xiaomi Inc.

Sirp polypeptide compositions and methods of use

Provided herein are sirp-gamma, sirp-beta or sirp-beta2 decoy polypeptides for immunotherapy and/or treatment of cancer, anemia, transplant, asthma, allergy, auto-immune disease, and viral infection.. .
Ab Initio Biotherapeutics, Inc.

Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor

Benzoimidazol-2-yl pyrimidines, purification methods for the same, and pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by h4 receptor activity, including allergy, asthma, autoimmune diseases, and pruritus.. .
Janssen Pharmaceutica Nv

Method and means for diagnosing and treating allergy

Disclosed is a method for diagnosing allergy in a human or animal patient, wherein the level of species-specific lipocalin, especially lipocalin 2 in a human patient, is measured in a sample of said patient and wherein a lowered level of said lipocalin compared to the level of said lipocalin in the corresponding sample of a human or animal that has no allergy, is indicative of an allergy, as well as a kit for performing this method, and a kit for quality control of allergen molecules or extracts used for immunotherapy of allergy by determining its siderophore-iron ligand load and thus immunomodulatory potency. Further, lipocalin proteins for use in treatment or prevention of allergies are provided, preferably complexed with siderophore-iron ligands..
Biomedical International R+d Gmbh

Methods and devices for allergy testing and treatment

A method of testing a patient for allergies includes obtaining from the patient a blood sample having an original volume of at most 0.5 ml, and testing the blood sample for ige reactive with antigens from a plurality of allergen sources by multiple elisa. The blood sample may be taken from the patient in a clinic, and/or the blood sample may be taken by a physician without venipuncture.
Spiriplex, Inc

Method of preventing allergies

The present invention relates to compositions and methods for preventing allergy in a subject. Particularly, the present invention relates to epicutaneous prevention of allergies in children.
Dbv Technologies

Supplement for improving immunotolerance, intestinal environment and intestinal tract barrier

A supplement for improving immunotolerance, intestinal environment and intestinal tract barrier for the purpose of improving intestinal vulnerability, food intolerance or allergy, systemic allergy, autoimmune diseases and systemic inflammatory diseases by immune reactions which is obtained by mixing an ingredient (a) comprising at least one of a probiotic that is any one of lactic acid bacteria, lactobacillus bifidus, saccharified bacteria, natto bacteria and yeast fungus, or a mixture thereof, a biogenic that is a bacteria-producing substance such as lactic acid bacteria, and a prebiotic is indigestible food ingredients such as oligosaccharide, dietary fiber, substance stimulating production of lactobacillus bifidus, and others or a mixture thereof and an ingredient (b) comprising at least one of l-glutamine, zinc, vitamin a and vitamin d.. .

Vista-ig for treatment of autoimmune, allergic and inflammatory disorders

The present invention relates to a fusion proteins comprising regulatory t cell protein, vista (v-domain immunoglobulin suppressor of t cell activation (pd-l3) and an immunoglobulin protein (ig). The invention also provides the use of vista polypeptides, multimeric vista polypeptides, vista-conjugates (e.g., vista-ig), and vista antagonists for the treatment of autoimmune disease, allergy, and inflammatory conditions..
Anthura B.v.

Treatment of celiac disease, c. difficile infection, food intolerance and food allergy with secretory iga/igm

A process is provided for inhibiting symptoms of celiac disease, clostridium difficile associated diseases such as clostridium difficile colitis, pseudomembranous colitis and antibiotic associated diarrhea, food allergy or food intolerance in a subject that includes the oral adminstration to the subject suffering from food allergy or food intolerance an igm. When administered in a, therapeutic quantity based on the subject characteristics and the type of igm, symptoms of food allergy or food intolerance in that subject are inhibited.

Programming of cells for tolerogenic therapies

Biomaterial systems, e.g., gel scaffolds, are used in vivo to recruit immune cells and promote their activation towards a non-inflammatory phenotype, thereby leading suppression of inflammation. The compositions and methods are useful to reduce the severity of autoimmunity, chronic inflammation, allergy, and periodontal disease..
Forsyth Dental Infirmary For Children

Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response

The invention provides immune regulatory oligonucleotides (iro) as antagonist of tlrs and methods of use thereof. These iros have unique sequences that inhibit tlr-mediated signaling in response to a tlr ligand or tlr agonist.
Idera Pharmaceuticals, Inc.

Methods for treating allergic airway inflammation

Provided herein are methods for treating a symptom and/or clinical sign associated with an allergy that includes neutrophil recruitment, such as allergic airway inflammation. In one embodiment, the method includes administering to a subject a composition that includes a cxcr2 inhibitor, a md2 inhibitor, a myd88 inhibitor, or a combination thereof.

Glucopyranosyl lipid a and allergen formulations for sublingual administration

The present application relates to compositions and methods for treating allergy, e.g., peanut allergy, in patients. The methods involve administering glucopyranosyl lipid adjuvant (gla) and peanut allergen(s) to the patient via a sublingual route..
Sanofi

Uses of kappa opioid synthetic peptide amides

The invention relates to methods of use of synthetic peptide amides that are ligands of the kappa opioid receptor in the treatment and prevention of kappa opioid receptor-associated diseases and conditions; and particularly to uses of these agonists in the prophylaxis, inhibition and treatment of pain, inflammation and pruritis associated with a variety of diseases, disorders and conditions. Inflammatory conditions preventable or treatable by the methods of the invention include diseases and conditions associated with elevated levels of a proinflammatory cytokines, such as tnf-α, il-1β, il-6, mmp-1 and mmp-3.
Cara Therapeutics, Inc.

Sirna and their use in methods and compositions for inhibiting the expression of the orai1 gene

The invention relates to si rna molecules and their use in methods and pharmaceutical compositions for inhibiting the expression of the orai1 gene. The invention also relates to the use of said si rnas molecules in the treatment and/or prevention of an eye condition characterised by increased expression and/or activity of orai1 gene, preferably said eye condition is conjunctivitis and/or an ocular allergy such as seasonal allergic conjunctivitis, perennial allergic conjunctivitis, vernal keratoconjunctivitis, atopic keratoconjunctivitis, and giant papillary conjunctivitis..
Sylentis Sau

Sirna and their use in methods and compositions for inhibiting the expression of the flap gene

The invention relates to si rna molecules and their use in methods and pharmaceutical compositions for inhibiting the expression of the flap gene. The invention also relates to the use of said si rnas molecules in the treatment and/or prevention of an eye condition characterised by increased expression and/or activity of flap gene, preferably said eye condition is conjunctivitis and/or an ocular allergy such as seasonal allergic conjunctivitis, perennial allergic conjunctivitis, vernal keratoconjunctivitis, atopic keratoconjunctivitis, and giant papillary conjunctivitis..
Sylentis Sau

Heat-treated formulation of bifidobacterium lactis ncc 2818 reduces allergic manifestations

Heat treated bifidobacterium lactis ncc 2818 reduces the symptoms of allergies in different groups of patients, such as allergies originating from food allergens in young children, or infants, and food, respiratory and cutaneous allergens in children, adults and household pets. The heat treated bifidobacterium lactis ncc 2818 may be administered alone or in a composition.
Nestec S.a.

Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof

The present invention relates to the compound according to formula i, and to its use in medicine, in particular in the treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6 or interferons. In particular, the compound inhibits jak a family of tyrosine kinases, and more particularly jak1.

Tolerogenic synthetic nanocarriers for allergy therapy

Disclosed are synthetic nanocarrier compositions, and related methods, comprising immunosuppressants and mhc class ii-restricted epitopes of an allergen that provide tolerogenic immune responses specific to the allergen.. .
Selecta Biosciences, Inc.

Methods of treating allergies and autoimmune diseases with homogenate of axenic c. elegans

Methods of using axenic c. Elegans homogenate for treating allergies or an autoimmune disease are disclosed.
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.

Rnai-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions

Rna interference is provided for inhibition of spleen tyrosine kinase (syk) mrna expression, in particular, for treating patients having a syk-related inflammatory condition or at risk of developing a syk-related inflammatory condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, allergy, or mast-cell disease.. .
Arrowhead Pharmaceuticals, Inc.

Benzazepine dicarboxamide compounds

Wherein r1 to r4 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are tlr agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases..

Compositions and methods for combination ingredient delivery

Described herein are compositions, methods, and devices for relief of a cough, cold, sore throat, or allergy, or a related symptom. Also described herein are compositions, methods, and devices for the prevention, treatment and/or amelioration of a digestive illness or digestive discomfort, or a related symptom of either..
The Fix, Llc

Peptide combinations and uses thereof in treating dust mite allergy

The invention relates to combinations of peptides or variants thereof derived from a portion of an amino sequence of cm a house dust mite allergen, e.g. The allergens der p 1, der f 1, der p 2 and/or der f 2.
La Jolla Institute For Allergy And Immunology

Glycotargeting therapeutics

Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent.. .
Ecole Polytechnique Federale De Lausanne (epfl)

Sirna and their use in methods and compositions for inhibiting the expression of the pdk1 gene

The invention relates to sirna molecules and their use in methods and pharmaceutical compositions for inhibiting the expression of the pdk1 gene. The invention also relates to the use of said sirnas molecules in the treatment and/or prevention of an eye condition characterised by increased expression and/or activity of pdk1 gene, preferably said eye condition is conjunctivitis and/or an ocular allergy such as seasonal allergic conjunctivitis, perennial allergic conjunctivitis, vernal keratoconjunctivitis, atopic keratoconjunctivitis, and giant papillary conjunctivitis..
Sylentis Sau

Antibody therapeutics that bind ctla4

There is disclosed compositions and methods relating to or derived from anti-ctla4 antibodies. More specifically, there is disclosed fully human antibodies that bind ctla4, ctla4-antibody binding fragments and derivatives of such antibodies, and ctla4-binding polypeptides comprising such fragments.
Sorrento Therapeutics, Inc.

Amorphous magnesium-substituted calcium phosphate compositions and their uses

Amorphous magnesium-substituted calcium, phosphate compositions and their medical uses are described, in particular for use in delivering cargo materials, such as cargo molecules or cargo nanoparticles contained in pores of the amorphous magnesium-substituted calcium phosphate to cells of the immune system, for example as therapeutic approaches for the treatment of inflammatory bowel diseases, and in particular crohn's disease, autoimmune diseases, allergy and for therapeutic vaccination.. .
Medical Research Council

Method of inducing tolerance to an allergen

The present invention relates generally to the field of allergies. More particularly, the present invention provides a method for treating an allergy in a subject by inducing tolerance to an allergen associated with the allergy.
Murdoch Childrens Research Institute

Toothpaste for delivery of allergens to oral mucosa

Pro-toothpaste compositions formulated to receive a volume of allergen solution to provide toothpastes that exhibit efficacy for oral mucosal immunotherapy (omit) and acceptable consumer and product stability properties, along with kits of pro-toothpaste, allergen/extracts of allergens, and optionally compounding means and/or specialized toothbrushes are provided. Toothpastes suitable and effective for omit and methods for managing allergic symptoms and for reducing risk of allergy in people without symptoms employing the pro-toothpastes, toothpastes and kits of the invention are also disclosed..
Allovate, Llc

Allergy testing tray

An allergy testing kit contains a plurality of allergy testing applicators, an allergy testing tray and a plurality of allergen bottles each containing an allergen. Each of the applicators contains an elongated handle, a plurality of arms extending from the elongated handle and disposed in an asymmetrical configuration, and a plurality of legs with tines extending from each of the arms.

Method of testing for allergies

An allergy testing kit contains a plurality of allergy testing applicators, an allergy testing tray and a plurality of allergen bottles each containing an allergen. Each of the applicators contains an elongated handle, a plurality of arms extending from the elongated handle and disposed in an asymmetrical configuration, and a plurality of legs with tines extending from each of the arms.

Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit)

The present invention provides in vitro and in vivo diagnostic tests and methods for determining the safety, efficacy, or outcome of allergen-specific immunotherapy (sit) in a patient. The present invention also provides for the measurement of allergen specific igg and ige in a patient tissue sample, or extract thereof, or in a biological fluid or blood sample, and determining whether the allergen-specific immunoglobulins contained in the patient sample(s), upon injection into an allergen-sensitized animal, will protect the animal following challenge with the allergen.
Regeneron Pharmaceuticals, Inc.

Composition comprising peptide derived from adiponectin

Provided is a pharmaceutical or cosmetic composition comprising adiponectin-derived peptide fragments, i.e., the peptides of seq id nos: 1 to 6 as an active ingredient. The peptides facilitate skin regeneration and moisturization, inhibit skin wrinkle, and have inhibitory activities against allergy and inflammation as well as metastasis of cancer cells..
Supadelixir Inc.

Allergy testing kit

An allergy testing kit contains a plurality of allergy testing applicators, an allergy testing tray and a plurality of allergen bottles each containing an allergen. Each of the applicators contains an elongated handle, a plurality of arms extending from the elongated handle and disposed in an asymmetrical configuration, and a plurality of legs with tines extending from each of the arms.

Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response

The invention provides novel immune regulatory oligonucleotides (iro) as antagonist of tlrs and methods of use thereof. These iros have unique sequences that inhibit or suppress tlr-mediated signaling in response to a tlr ligand or tlr agonist.
Idera Pharmaceuticals, Inc.

Human immune therapies using a cd27 agonist alone or in combination with other immune modulators

Methods of inducing t cell proliferation and expansion in vivo for treating conditions wherein antigen-specific t cell immune response are therapeutically desirable such as cancer, infection, inflammation, allergy and autoimmunity and for enhancing the efficacy of vaccines are provided. These methods comprise the administration of at least one cd27 agonist, preferably an agonistic cd27 antibody, alone or in association with another moiety such as immune stimulant or immune modulator such as an anti-cd40, ox-40, 4-1bb, or ctla-4 antibody or an agent that depletes regulatory cells, or a cytokine.
University Of Southampton

Novel compound useful for the treatement of degenerative and inflammatory diseases

A pyrazolopyridine compound according to formula i, able to inhibit jak is disclosed, as well as pharmaceutically acceptable salts, a solvate thereof, solvates of the pharmaceutically acceptable salts and biologically active metabolites thereof. The compound may be prepared as a pharmaceutical composition, and may be used for the treatment or prophylaxis of a variety of conditions in mammals including humans, and particularly, such conditions as may be associated with aberrant jak activity, including by way of non-limiting example, allergy, inflammatory conditions, autoimmune diseases, proliferative diseases, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6..

Phl p 5a derivatives having reduced allergeneity and retained t-cell reactivity

The present invention relates to the preparation and use of variants of the group 5 allergen of the pooideae which are characterised by reduced ige reactivity compared with the known wild-type allergens and at the same time by substantially retained reactivity with t lymphocytes. These hypoallergenic allergen variants can be employed for the specific immunotherapy (hyposensitisation) of patients having grass pollen allergy or for the preventative immunotherapy of grass pollen allergies..
Merck Patent Gmbh

Allergy skin test devices with surrounding pain-reduction structures

An allergy skin testing device is disclosed that includes at least one central post having at least one sharp probe extending longitudinally from an end of the at least one central post, the at least one sharp probe being for administering an allergen to skin. For each central post, at least three dull probes substantially surround the at least one sharp probe, creating a “pain gate fence”, the at least three dull probes being for activating a pain gate effect affecting nerves of the skin while the at leat one sharp probe administers the allergen to the skin.

Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response

The invention provides immune regulatory oligonucleotides (iro) as antagonist of tlrs and methods of use thereof. These iros have unique sequences that inhibit tlr-mediated signaling in response to a tlr ligand or tlr agonist.
Idera Pharmaceuticals, Inc.

A purified extract isolated from pseudolysimachion rotundum var. subintegrum containing abundant amount of active ingredient, the preparation thereof, and the composition comprising the same as an active ingredient for preventing or treating inflammation, allergy and asthma

A method for preparing purified extract containing more abundant active ingredients such as catalpol derivatives from the extract of pseudolysimachion rotundum var subintegrum than that prepared by the conventional preparation method disclosed in the prior art and the therapeutics or functional health food comprising the purified extract for treating and preventing inflammatory, allergic or asthmatic disease. The purified extract showed more potent anti-inflammatory, anti-allergy and anti-asthma activity than that prepared by the conventional preparation method disclosed in the prior art through various in vivo tests such as inhibition test on the reproduction of eosinophil, the release of immunoglobulin and inflammatory chemokines in plasma and bronchoalveolar fluid as well as the suppression of airway hyperresponsiveness and goblet cell hyperplasia in a ova-sensitized/challenged mouse model..
Korea Research Institute Of Bioscience And Biotechnology

Molecular identification of allergy causing mites by pcr

The present invention relates to novel methods for the identification of specific mite species in a sample, such as mass reared sample or an environmental sample. The invention further relates to nucleic acid molecules encoding the structural ribosomal rna elements (rrna) as well as to the non-functional rna situated between such structural ribosomal rnas of specific mite species and its use for designing primers for use in the method..
Alk-ablló S/a

Composition for use in treating and preventing inflammation related disorder

The present invention is related to a use for treating and preventing inflammation related disorder of a composition containing a drug and hyaluronic acid (ha) or ha mixture, whereas the ha or the ha mixture as a delivery vehicle can be a formulation including at least two has having different average molecular weights. The composition has been demonstrated to be capable of reducing the therapeutic dose of a drug on the treatment and prevention of inflammation related disorders is acute inflammatory disease, chronic obstructed pulmonary disease, coeliac disease, conjunctivitis, otitis, allergic rhinitis, gingivitis, aphthous ulcer, bronchitis, gastroesophageal reflux disease (gerd), esophagitis, gastritis, enteritis, peptic ulcer, inflammatory bowel disease (ibd), crohn's disease, irritable bowel syndrome (ibs), intestinal inflammation or allergy, urethritis, cystitis, vaginitis, proctitis, eosinophilic gastroenteritis, or rheumatoid arthritis..
Aihol Corporation

N-cyanomethylamides as inhibitors of janus kinase

The present invention relates to compounds of general formula (1) that are inhibitors of janus kinase (jak), a family of tyrosine kinases that are involved in inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6 or interferons. In particular, the compound of the invention inhibits jak1 and/or jak2 and/or jak3 sub families.

Fujian Mindong Rejuvenation Pharmaceutical Co., Ltd.

. .

Method for prognosis of the efficacy of oral immunotherapy for the treatment of allergy to proteins in cow's milk

The present invention relates to a method for prognosis of the efficacy of oral immunotherapy for the treatment of allergy to proteins in cow's milk providing a solution to the problems stated in the state of the art since it provides a method which allows making a prognosis of the number of reactions that will be produced during oral immunotherapy (oit) against proteins in cow's milk and/or an estimate of the treatment time required to achieve tolerance or desensitization during oit against proteins in cow's milk and/or the need for pre-medication during oit in a human subject.. .
Fundación Para La Investigación Biomédica Del Hospital Clinico San Carlos

Regulatory t cell mediator proteins and uses thereof

In particular methods of using these proteins and compounds, preferably antibodies, which bind or modulate (agonize or antagonize) the activity of these proteins, as immune modulators and for the treatment of cancer, autoimmune disease, allergy, infection and inflammatory conditions, e.g. Multiple sclerosis is disclosed.

Anti-allergy benzocycloheptathiophene derivatives

Or a pharmaceutically acceptable salt thereof, solvate, or prodrug thereof, and a pharmaceutically acceptable carrier, vehicle or excipient.. .

Long-term effective patch structure

A long-term effective patch structure includes a binding layer, an absorbing layer and a water-proof layer sequentially stacked together. The binding layer has a function of attaching and fixing, and is configured to be attached and fixed on a skin.
Sigknow Biomedical Corporation Ltd.

Identification of vsig8 as the putative vista receptor (v-r) and use thereof to produce vista/vsig8 agonists and antagonists

The receptor for vista is identified (vsig8) as well as the use of this receptor in the identification or synthesis of agonist or antagonist compounds, preferably antibodies, polypeptides and fusion proteins which agonize or antagonize the effects of vsig8 and/or vista and/or the vsig8/vista binding interaction. These antagonists may be used to suppress vista's suppressive effects on t cell immunity, and more particularly used in the treatment of cancer, or infectious disease.
Immunext, Inc.

Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor

Benzoimidazol-2-yl pyrimidines, purification methods for the same, and pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by h4 receptor activity, including allergy, asthma, autoimmune diseases, and pruritus.. .
Janssen Pharmaceutica Nv

Devices, systems and methods of assessing the foundations for the healthy development of an infant or a young child

Devices, systems and methods assess one or more of the risk of an allergy, immediate and/or later in life, for the infant or young child; the risk of an underdeveloped immune system, immediate and/or later in life, for the infant or young child, and/or the immediate risk of a not well-functioning digestive system for the infant or young child, preferably all of these. Optionally, the risk of obesity, immediate and/or later in life, can be additionally assessed.
Nestec S.a.

Pharmaceutical product comprising mite allergen extract(s) and a the manufacture thereof

The invention relates to a pharmaceutical product comprising an allergen extract or an allergoid thereof for the treatment and/or prevention of allergy and allergic asthma caused by house dust mites, which extract comprises at least one extract of mite bodies selected from the following groups a)-b): a) an extract of der p mite bodies, and b) an extract of der f mite bodies, and at least one extract of mite cultures selected from the following groups c)-g): c) an extract of der p faecal particles, d) an extract of der f faecal particles, e) an extract of der f whole mite culture, f) an extract of an der p whole mite culture, and g) a combination of extracts c) to f).. .
Alk-abelló A/s

Preparation of bee venom with allergenic components removed

Disclosed is a method for manufacturing a separated and purified bee venom (separated pbv) not possessing allergy-triggering effects by reducing or eliminating allergy-inducing components contained in a bee venom via ultrafiltration, thereby producing a pvb with desirable pharmacological effects while fundamentally blocking allergies that may be induced by the same. The manufacturing method of the present invention includes a first step of preparing a purified bee venom powder; a second step of preparing a bee venom liquid by mixing the purified bee venom powder with distilled water; a third step of removing allergic ingredients contained in the bee venom liquid via ultrafiltration through a membrane having a cut-off size of 10 kda; and a fourth step of obtaining a separated pbv with the allergenic components removed; wherein the distilled water to be mixed with the purified bee venom powder in the second step is used in the range of from 1000 ml to 1500 ml per 1 g of the purified bee venom powder, the allergenic components removed through the ultrafiltration membrane in the third step are phospholipase a2 and hyaluronidase, and the separated pbv obtained in the fourth step contains 4 wt % or higher of apamin, and 50 wt % or higher of melittin..
Chung Jin Biotech Co., Ltd Hanyang Univ Ansan Campus, Sa-dong

Treatment of food intolerance and food allergy with iga

A process is provided for inhibiting symptoms of food allergy or food intolerance in a subject that includes the oral adminstration to the subject suffering from food allergy or food intolerance an igm. When administered in a therapeutic quantity based on the subject characteristics and the type of igm, symptoms of food allergy or food intolerance in that subject are inhibited.

Effector-deficient anti-cd32a antibodies

Effector-deficient anti-cd32a monoclonal antibodies are encompassed, as are method and uses for treating cd32a-mediated diseases and disorders, including, thrombocytopenia, allergy, hemostatic disorders, immune, inflammatory, and autoimmune disorders.. .
Adventist Health System/sunbelt Inc.

Breathable pillow

An integrated padded mesh material may be used in pillows or pillowcases for improved air flow around a user of the pillow or pillowcase during rest. When used in a pillow, the material may substantially cover the side of the pillow that a user's head rests upon.
Breathablebaby, Llc

Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response

The invention provides novel immune regulatory oligonucleotides (iro) as antagonist of tlrs and methods of use thereof. These iros have unique sequences that inhibit or suppress tlr-mediated signaling in response to a tlr ligand or tlr agonist.
Idera Pharmaceuticals, Inc.

T cell epitopes derived from alt a 1 or alt a 5 for the treatment of alternaria alternata allergy

The application discloses peptides capable of preventing or treating fungal disease, including fungal allergy disease.. .
Alergenetica Sl

Thin planar biological sensor

A thin planar biological sensor is provided, comprising at least one flexible electrode used for contacting a subject's skin and measuring biological signal. The flexible electrode is made of silicon-silver-based material, in which a ratio of silicon to silver-compound is about 7:3.
National Chiao Tung University

Methods and devices for treating primary headache

Non-invasive electrical nerve stimulation devices and magnetic stimulation devices are disclosed, along with methods of treating medical disorders using energy that is delivered noninvasively by such devices. The disorders comprise migraine and other primary headaches such as cluster headaches, including sinus symptoms that resemble an immune-mediated response (“sinus” headaches), irrespective of whether those symptoms arise from an allergy that is co-morbid with the headache.
Electrocore, Llc

Vaccine peptide combinations against cat allergy

The present invention relates to compositions comprising peptides for preventing or treating allergy to cats, and in particular to optimal combinations of peptides. .
Circassia Limited

Recombinantly produced allergens

Methods for producing an allergen composition, methods for in vitro diagnosis of type i allergy, and diagnostic kits for performing diagnosis employ bos d 23k allergen of seq id no: 4, or the mature protein thereof, or a variant or fragment of the bos d 23k allergen or the mature protein sharing epitopes for antibodies with the bos d 23k allergen or the mature protein. Methods for treatment of a type i allergy to a mammal and pharmaceutical compositions employ a bos d 23k allergen of seq id no: 4, or the mature protein thereof, or a variant or fragment of the bos d 23k allergen or the mature protein sharing epitopes for antibodies with the bos d 23k allergen or the mature protein, wherein the bos d 23k allergen, the mature protein, the variant or the fragment is modified to abrogate or attenuate its ige binding response..
Phadia Ab

Beverage compositions and other formulations for treating allergies and methods for making the same

A composition for preventing and/or alleviating an allergy related condition and methods of making such compositions are disclosed herein. A composition in accordance with a particular embodiment can include honey having pollen derived from a known plant species and/or from a known geographic location.

Breathable mattress pad and sleeping accessories

Sleeping accessories such as mattress pads, mattress topper covers, and sheet savers are disclosed herein comprising integrated padded mesh material. Integrated padded mesh material, when used in the sleeping accessories, results in improved air flow for the user, which can reduce complications during sleep such as sudden infant death syndrome.
Breathablebaby, Llc

Anti-il-25 antibodies and uses thereof

The present invention provides antibodies that bind to human interleukin-25 (il-25) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human il-25 with high affinity.
Regeneron Pharmaceuticals, Inc.

Horse allergen and methods

A method for performing in vitro diagnosis of type 1 allergy, comprises contacting an immunoglobulin-containing body fluid sample from a patient suspected of having type 1 allergy with an immobilized horse allergen immobilized on a solid support, and detecting the presence, in the sample, of ige antibodies specifically binding to the horse allergen, wherein the presence of such ige antibodies specifically binding to the horse allergen is indicative of type 1 allergy. A method for treatment of type 1 allergy comprises administering to an individual susceptible to such treatment, the horse allergen, or a form of the horse allergen that is modified to abrogate or attenuate its ige binding response.
Phadia Ab

Rapid allergy testing method

The present invention provides a method for testing an allergy capable of rapidly and highly accurately testing an allergic reaction. The method can determine whether or not a patient has an allergy or whether or not an agent that may be allergenic to a patient has an allergenicity (an allergic reactivity) in the patient.

Refined product obtained from rice hull and preparation process and use thereof

Disclosed herein is a refined product obtained from a rice hull, which consists essentially of a type ii arabinogalactan having a number average molecular weight in the range of 56 to 103 kda. Also disclosed are a process for producing the refined product and use of the refined product for enhancing the biological activity of innate immune cells, as well as for treating allergy and cancer..
China Medical University

Rnai-mediated inhibition of histamine receptor h1-related conditions

Rna interference is provided for inhibition of histamine receptor h1 mrna expression, in particular, for treating patients having an hrh1-related condition or at risk of developing an hrh1-related condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, or allergy.. .
Arrowhead Research Corporation

Novel prostate kallikrein allergen

Methods for treatment of a type i allergy in a mammal comprise administering to an individual in need of such treatment a polypeptide of seq id no: 1 or the mature protein, amino acids 25-260, of the polypeptide of seq id no: 1, or a fragment of the polypeptide or the mature protein, which fragment shares epitopes for antibodies with the polypeptide or the mature protein, respectively, or a hypoallergenic form thereof that is modified to abrogate or attenuate its ige binding response. Diagnostic kits comprise the polypeptide of seq id no: 1 or the mature protein, amino acids 25-260, of the polypeptide of seq id no: 1, immobilized on a solid support..
Phadia Ab

Urine detection inductor suitable for large-scale production

A detector for wet diaper is suitable for large-scale production. The detector comprises a nonwoven fabric (1) and at least two electrodes (2, 3) which are carbon powder coated on the nonwoven fabric (1).

Tolerogenic synthetic nanocarriers for allergy therapy

Disclosed are synthetic nanocarrier compositions, and related methods, comprising immunosuppressants and mhc class ii-restricted epitopes of an allergen that provide tolerogenic immune responses specific to the allergen.. .
Selecta Biosciences, Inc.

A prefilled medication device, making and using the same

The invention generally relates to prefilled disposable medication devices, method of making, and using to store, contain and deliver at least a diluent for allergenic extract and more particularly to a prefilled cartridge containing a diluent for allergenic extract for use with an injection pen for allergy treatments.. .
Phd Preventive Health Care And Diagnostics, Inc.

Glycotargeting therapeutics

Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent.. .
Anokion Sa

Topical ocular preparation of botulinum toxin for use in ocular surface disease

A composition of botulinum toxin is claimed which can penetrate into the ocular surface inclusive of a penetration through a conjunctiva, cornea, and other structures. This composition allows for a maximal penetration of a topical preparation of botulinum toxin which serves to reduce the need for frequent allergy drops for the treatment of ocular surface disease and other conditions causing ocular surface inflammation or deep ocular inflammation.
Botulinum Toxin Research Associates, Inc.

Sprayable oxygenated saline composition and treating nasal congestion, allergy, dryness, eye irritation, throat irritation, wounds, and skin as applied to human tissues

An oxygenated saline composition is provided comprising stabilized oxygen, sodium chloride (aqueous saline solution), and optionally one or more homeopathic components. The stabilized oxygen can include quad-atomic oxygen.
Oxy Bump Corporation